Browse by Track

(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.

(P 02) PEDIATRIC SYNOVIAL SARCOMA: A REVIEW OF 21 CASES FROM A SINGLE INSTITUTION

(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS

(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA

(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR

(P 06) ONCOFERTILITY AND PREGNANCY IN ADOLESCENT AND YOUNG ADULT CANCERS: PHYSICIANS' KNOWLEDGE AND PREFERENCES IN A LARGE LOW-MIDDLE- INCOME COUNTRY

(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION

(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS

(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.

(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)

(P 11) LX-101, A NOVEL, CLINICAL STAGE, PAYLOAD-BEARING TARGETED THERAPY DIRECTED TO THE INSULIN-LIKE GROWTH FACTOR RECEPTOR, HAS POTENT PRECLINICAL ANTI-TUMOR ACTIVITY AGAINST PEDIATRIC SARCOMAS

(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE

(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

(P 14) PERCUTANEOUS CRYOABLATION OF PROGRESSING EXTRA-ABDOMINAL DESMOID TUMOURS

(P 15) INTRAOSSEOUS RHABDOMYOSARCOMA OF THE CHEST WITH FUS:TFCP2 FUSION AND GERMLINE VARIANTS IN NF1 AND SBDS: NOVEL LOCATION AND MOLECULAR CHARACTERISTICS OF A RARE TUMOR

(P 16) ALVEOLAR SOFT PART SARCOMA: PROGRESS TOWARD IMPROVEMENT IN SURVIVAL? A NATIONWIDE DATABASE STUDY IN JAPAN

(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA

(P 18) RETROSPECTIVE ANALYSIS ON OUTCOMES PEDIATRIC PATIENTS WITH SARCOMA AND LUNG METASTASES STATUS POST PNEUMONECTOMY VERSUS PARTIAL LUNG RESECTION

(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS

(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE

(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT

(P 22) RECALL EXPERIENCE FOR SURVIVORS OF PEDIATRIC RHABDOMYOSARCOMA TREATED AT A SINGLE INSTITUTION BETWEEN 1970 AND 2010

(P 23) GENOMIC COMPLEXITY AS A BIOMARKER FOR ADJUVANT IMATINIB TREATMENT IN HIGH-RISK GASTROINTESTINAL STROMAL TUMOR

(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)

(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR

(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS

(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST

(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS

(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR

(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY

(P 31) NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS

(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)

(P 33) LONGITUDINAL FOLLOW UP OF GASTROINTESTINAL STROMAL TUMORS:DATA FROM THE LIFE RAFT GROUP INTERANTIONAL PATIENT REGISTRY

(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS

(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS

(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST

(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY

(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA

(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS

(P 41) GENOMIC ANALYSIS OF SECONDARY KIT MUTATIONS IN CHINESE PATIENTS WITH IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS USING NEXT-GENERATION SEQUENCING (NGS)

(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS

(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY

(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES

(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB

(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)

(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS

(P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.

(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB

(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA

(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS

(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?

(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS

(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?

(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE

(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)

(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING

(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA

(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?

(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES

(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT

(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY

(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE

(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA

(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA

(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION

(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)

(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)

(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA

(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA

(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH

(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS

(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY

(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE

(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA

(P 78) THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA

(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS

(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS

(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE

(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY

(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION

(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE

(P 86) DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL

(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT

(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS

(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS

(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY

(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT

(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE

(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS

(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM

(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES

(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP

(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA

(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS

(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)

(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA

(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA

(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION

(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA

(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA

(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS

(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA

(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA

(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS

(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS

(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA

(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO

(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS

(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]

(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)

(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)

(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT

(P 120) THE FEASIBILITY OF CD47-BASED IMMUNOTHERAPY FOR OSTEOSARCOMA

(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS

(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA

(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE

(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT

(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT

(P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.

(P 127) TRENDS IN CONTACTS TO THE SARCOMA UK SUPPORT LINE

(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA

(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE

(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS

(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES

(P 132) SARCOMA PATEINTS' VIEWS ON USING A RISK-PREDICTION MODEL TO INFORM TREATMENT DECISIONS.

(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"

(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.

(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY

(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP

(P 137) IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON SARCOMA CARE: A SINGLE INSTITUTION EXPERIENCE

(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)

(P 139) ULTRA-RARE SARCOMAS HAVE WORSE SURVIVAL COMPARED TO NON-ULTRA-RARE SARCOMAS: A NATIONAL CANCER REGISTRY STUDY

(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.

(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA

(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY

(P 143) EXPLORING HOSPITAL VOLUME THRESHOLDS FOR IMPROVED SARCOMA TREATMENT ACROSS DIFFERENT AGE CATEGORIES IN THE UNITED STATES

(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS

(P 145) OUTCOMES OF BREAST ANGIOSARCOMA UNDERGOING TREATMENT IN A SPECIALIST CENTRE

(P 146) CHARACTERIZING THE PATIENT JOURNEY TO A DIAGNOSIS OF DESMOID TUMOR: DESMOID TUMOR RESEARCH FOUNDATION NATURAL HISTORY STUDY

(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE

(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE

(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN

(P 150) VISUALISING SOFT TISSUE SARCOMA INCIDENCE DATA FOR PATIENT EMPOWERMENT

(P 151) DEVELOPMENT AND IMPACT OF A PRIMARY CARE SARCOMA EDUCATION MODULE FOR ENGLAND AND WALES

(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS

(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS

(P 154) BARRIERS TO CARE FOR MUSCULOSKELETAL TUMORS

(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES

(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP

(P 157) QUALITY OF LIFE DURING TREATMENT FOR METASTATIC SARCOMA - FEASIBILITY OF ELECTRONIC PATIENT REPORTED OUTCOMES

(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS

(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)

(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS

(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS

(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS

(P 163) SELUMETINIB IN JAPANESE PEDIATRIC PATIENTS WITH SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE 1

(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)

(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA

(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP

(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B

(P 170) HETEROGENEITY OF PAZOPANIB ACTIVITY ACROSS SOFT TISSUE SARCOMA SUBTYPES - A RETROSPECTIVE ANALYSIS OF 303 CASES FROM A REFERENCE CENTER

(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER

(P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS

(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

(P 174) SELISARC: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE I/II TRIAL OF SELINEXOR PLUS GEMCITABINE IN SELECTED SARCOMA SUBTYPES: RESULTS OF THE PHASE I PART

(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY

(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE

(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES

(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS

(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS

(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE

(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA

(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA

(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES

(P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D

(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST

(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.

(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA

(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY

(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES

(P 190) DOES RESPONSE TO PRIOR CHEMOTHERAPY PREDICT OUTCOME FROM FURTHER SYSTEMIC TREATMENT IN ADVANCED LEIOMYOSARCOMA? A SINGLE UK CENTRE EXPERIENCE

(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA

(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.

(P 193) Recent Trends in Sarcoma Trials for Children in the United States

(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE

(P 195) MULTIPLE MYXOMA EFFECTIVELY TREATED WITH PAZOPANIB - A CASE REPORT

(P 196) TOLERABILITY AND OUTCOMES FOR TREATMENT OF OLDER MYXOID LIPOSARCOMA POPULATION

(P 197) PROPRANOLOL MONOTHERAPY IN ANGIOSARCOMA - A WINDOW-OF-OPPORTUNITY STUDY (PROPANGIO)

(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT

(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES

(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY

(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS

(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM

(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE

(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES

(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902

(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE

(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY

(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY

(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS

(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES

(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND

(P 214) SIGNIFICANT TREATMENT RESPONSE IN PATIENTS WITH PRIMARY RESECTABLE EXTREMITY MYXOID LIPOSARCOMA RECEIVING NEOADJUVANT TRABECTEDIN AND RADIATION

(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY

(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER

(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND

(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS

(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE

(P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA

(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION

(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE

(P 223) SIGNATERA CTDNA TRACKER IN SARCOMA: CLINICAL EXPERIENCE

(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA

(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA

(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA

(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS

(P 228) WHAT IS THE SIGNIFICANCE OF INDETERMINATE PULMONARY NODULES IN HIGH GRADE SOFT TISSUE SARCOMA? A RETROSPECTIVE COHORT STUDY

(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS

(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA

(P 231) MINIMALLY INTERACTIVE SEGMENTATION OF SOFT-TISSUE TUMORS ON MRI AND CT USING DEEP LEARNING

(P 232) NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY

(P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION

(P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA

(P 235) FUSION OF PREOPERATIVE IN SITU MAGNETIC RESONANCE IMAGING AND POSTOPERATIVE COMPUTED TOMOGRAPHY TO CORRELATE FUNCTIONAL IMAGING FEATURES AND PATHOLOGICAL CHARACTERISTICS OF SOFT TISSUE SARCOMA

(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY

(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR

(P 238) EPIDEMIOLOGIC SURVEY OF MYXOFIBROSARCOM USING DATA FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN

(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER

(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY

(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION

(P 242) WHOLE BODY PET/MRI FOR STAGING OF MYXOID LIPOSARCOMA

(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS

(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS

(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION

(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER

(P 458) FREQUENCY IN CHANGE OF GRADING UPON LOCAL RECURRENCE OR DISTANT METASTASIS OF SOFT TISSUE SARCOMAS.

(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS

(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES

(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION

(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE

(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS

(P 465) UNPLANNED EXCISION OF SYNOVIAL SARCOMA: FACTORS ASSOCIATED WITH RECURRENCE AND SURVIVAL

(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING

(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY

(P 468) OPIATE USE AFTER TOTAL HIP ARTHROPLASTY FOR METASTATIC BONE DISEASE

(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS

(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS

(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA

(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA

(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS

(P 474) PREDICTORS OF EARLY INTROWTH AND FAILURE FOLLOWING SHORT COMPRESS SPINDLE OSSEOINTEGRATION FIXATION AT THE LOWER EXTREMITIES

(P 475) PRE-PLATING PRIOR TO INTERCALARY TUMOR RESECTION AND ALLOGRAFT RECONSTRUCTION: LESSONS LEARNED

(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE

(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY

(P 478) TREATMENT OF CHONDROBLASTOMA WITH PERCUTANEOUS CRYOABLATION

(P 479) EXPANDABLE ENDOPROSTHESES: SHOULD WE CONSIDER NARROWING OUR INDICATIONS? A SYSTEMATIC REVIEW OF THE LITERATURE AND COMPARISON OF OUTCOMES BY AGE GROUPS

(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES

(P 481) CUSTOM ADAPTERS FOR COMPRESS SPINDLE OSSEOINTEGRATION FIXATION IN REVISION LIMB SALVAGE SURGERY OF THE DISTAL FEMUR: A CASE SERIES

(P 482) COMPARISON OF RECONSTRUCTIVE TECHNIQUES FOR METASTATIC DISEASE IN THE PROXIMAL HUMERUS

(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?

(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA

(P 485) SUBTROCHANTERIC NON-UNION AFTER INTRAMEDULLARY NAILING DUE TO PATHOLOGICAL FRACTURE:PROXIMAL FEMORAL REPLACEMENT AS A SALVAGE APPROACH

(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES

(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES

(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS

(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION

(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY

(P 491) COMPARISON OF FIXATION TECHNIQUES FOR METASTATIC DISEASE OF THE HUMERUS

(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY

(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.

(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.

(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.

(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?

(P 497) STANMORE TUMOUR OUTCOMES PROJECT (STOMP)- USING INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH (ICF) OUTCOMES IN SARCOMA SURVIVORS. and UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE

(P 498) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: CHARACTERISTICS AND OUTCOME

(P 499) CLINICAL OUTCOMES OF TOTAL FEMORAL REPLACEMENT FOR ONCOLOGICAL INDICATIONS

(P 500) IMPROVING OUTCOMES OF INTERCALARY EWING SARCOMA RESECTIONS AND ALLOGRAFT RECONSTRUCTIONS WITH PATIENT-SPECIFIC CUTTING GUIDES AND VIRTUAL SURGICAL PLANNING

(P 501) TIBIAL DEFORMITIES AND PHYSEAL INJURY WITH DISTAL FEMORAL EXPANDABLE ENDOPROSTHESIS IMPLANTS

(P 502) SEPARATE RESECTION OF BIOPSY TRACT IN PRIMARY BONE SARCOMA: IMPLICATIONS FOR LOCAL RECURRENCE AND OVERALL SURVIVAL

(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION

(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES

(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY

(P 506) THE EFFECT OF TIMING BETWEEN PRE-OPERATIVE EMBOLIZATION AND SURGERY: A RETROSPECTIVE ANALYSIS OF HYPERVASCULAR BONE METASTASES

(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT

(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE

(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS

(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES

(P 511) SIGNIFICANCE OF TIP TO APEX DISTANCE IN PATHOLOGICAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR

(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW

(P 513) THE IMPACT OF MARGIN STATUS ON THE ONCOLOGIC OUTCOMES OF SURGICALLY TREATED DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES

(P 514) INTERSTITIAL BRACHYTHERAPY IN THE TREATMENT OF SOFT TISSUE SARCOMA: LOCAL RECURRENCE AND WOUND OUTCOMES

(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS

(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST

(P 517) PULMONARY METASTASECTOMY FOR SARCOMA: A SINGLE-INSTITUTION EXPERIENCE

(P 518) OUTCOMES OF NON-ANGIOSARCOMA RADIATION-ASSOCIATED SOFT TISSUE SARCOMAS OF THE CHEST

(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?

(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS

(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE

(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES

(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME

(P 524) PRESENTATION AND OUTCOMES OF EXTRASKELETAL CHONDROSARCOMAS TREATED WITH SURGICAL RESECTION

(P 525) ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION

(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME

(P 527) SALVAGE OF AN OSTEOARRTICULAR ALLOGRAFT RADIUS RECONSTRUCTION SINGLE BONE TRANSPOSITION WITH WRIST ARTHRODESIS FOLLOWING OSTEOSARCOMA EXCISION

(P 246) IMMUNOCOMPETENT MODELING OF PLEOMORPHIC LIPOSARCOMA

(P 247) HARNESSING EWING SARCOMA'S REPLICATION STRESS BY TARGETING DDK AND WEE1 IN COMBINATION

(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR

(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES

(P 250) SHARING HIGH-QUALITY SAMPLES AND DATA TO THE NF1 RESEARCH COMMUNITY: THE ROLE OF THE JOHNS HOPKINS NF1 BIOSPECIMEN REPOSITORY

(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY

(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1

(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.

(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS

(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY

(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT

(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS

(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS

(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.

(P 260) TARGETING HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN LEIOMYOSARCOMA WITH COMBINATION OF PARP INHIBITORS (PARPI) AND CHEMOTHERAPY (CTX).

(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION

(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE

(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS

(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?

(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA

(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA

(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS

(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS

(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)

(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)

(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS

(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)

(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL

(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS

(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES

(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS

(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.

(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA

(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY

(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA

(P 281) FIVE DAY SPACING OF TWO FRACTIONATED ABLATIVE RADIOTHERAPIES ENHANCES ANTITUMOR IMMUNITY IN FIBROSARCOMA CELL LINE

(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS

(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT

(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY

(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS

(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS

(P 287) ESTABLISHMENT AND GENOMIC VALIDATION OF NOVEL PATIENT-DERIVED XENOGRAFT MODELS FOR DRUG DISCOVERY IN GASTROINTESTINAL STROMAL TUMOR

(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN

(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS

(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS

(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS

(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY

(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA

(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS

(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA

(P 298) EVALUATING THE PHOTOTHERMAL AND CYTOTOXIC PROPERTIES OF INDOCYANINE GREEN IN VITRO FOR INTRAOPERATIVE PHOTOTHERMAL THERAPY IN SARCOMA

(P 299) EXPLORING THE IMMUNOLIGHT MECHANISM OF ACTION IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA

(P 300) ANTI-TUMOR ACTIVITY OF PARP7 INHIBITOR RBN-2397 IN SOFT-TISSUE SARCOMAS

(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY

(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS

(P 304) A COMPARATIVE ANALYSIS OF METABOLIC FLEXIBILITY IN OSTEOSARCOMA CELLS

(P 305) A NEW MOUSE MODEL FOR TESTING SPLICE-SWITCHING THERAPIES IN RHABDOMYOSARCOMA

(P 306) USE OF PENCIL BEAM SCANNING PROTON RADIOTHERAPY IN MOBILE SPINE CHORDOMAS

(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW

(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA

(P 309) CLINICAL PATHOLOGICAL CHARACTERISTICS, PATTERN OF CARE AND SURVIVAL OF NON-METASTATIC BREAST ANGIOSARCOMA

(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL

(P 311) ROBUST VMAT TREATMENT PLANNING FOR EXTREMITY SOFT TISSUE SARCOMAS

(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE

(P 313) SPACIALLY-FRACTIONATED RADIOTHERAPY (LATTICE) TREATMENT IN INOPERABLE NON-EXTREMITY BULKY SOFT-TISSUE SARCOMAS

(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA

(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES

(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY

(P 317) PROGNOSTIC FACTORS, CLINICAL AND TOXICITY OUTCOMES FROM A LARGE COHORT OF PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION THERAPY

(P 318) DEVELOPMENT OF NOVEL OUTLINING GUIDELINES FOR NORMAL TISSUE STRUCTURES FOR LIMB SOFT TISSUE SARCOMA.

(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.

(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY

(P 321) IDENTIFYING RISK FACTORS FOR REDUCTION OF PROTON THERAPY RE-PLANS FOR PAEDIATRIC PATIENTS WITH PELVIC SARCOMAS

(P 322) STEREOTACTIC BODY RADIOTHERAPY IN METASTATIC SARCOMA

(P 323) PERIPHERAL NEUROPATHY FOLLOWING INTRA-OPERATIVE RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE

(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA

(P 325) OUTCOMES AFTER MODERN THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY AND INTENSITY MODULATED RADIOTHERAPY TO TREAT SARCOMAS ARISING IN THE HAND: A RETROSPECTIVE SERIES

(P 326) CARBON-ION RADIOTHERAPY FOR UNRESECTABLE PELVIC SARCOMAS/CHORDOMAS

(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY

(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS

(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?

(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY

(P 331) MUSCULAR DEDIFFERENTIATION IN DEDIFFERENTIATED LIPOSARCOMA: INSIGHTS INTO INFLAMMATORY PROFILES USING THE NEUTROPHIL/LYMPHOCYTE RATIO AND PROGNOSTIC IMPLICATIONS

(P 332) SURGICAL OUTCOMES OF RETROPERITONEAL LIPOSARCOMA - SINGLE INSTITUTIONAL STUDY N JAPAN -

(P 333) SYSTEMIC TREATMENT IN INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE CASE SERIES ANALYSIS

(P 334) CHARACTERISTICS AND OUTCOMES FOR PATIENTS IN THE UNITED STATES WITH DEDIFFERENTIATED LIPOSARCOMA FROM A REAL-WORLD DATA SET

(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE

(P 337) CLINICAL OUTCOME OF THE PATIENTS WITH HIGH GRADE UTERINE SARCOMA: A SINGLE CENTRE REAL WORLD EXPERIENCE

(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA

(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT

(P 340) CENTRAL BOOST RADIATION THERAPY CAN ACHIEVE DURABLE LOCAL RESPONSE IN UNRESECTABLE RETROPERITONEAL SARCOMA

(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA

(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY

(P 343) STEREOTACTIC BODY RADIATION THERAPY (SBRT) IN ADVANCED/RECURRENT RETROPERITONEAL SARCOMA: PRELIMINARY RESULTS

(P 345) CLINICIAN SURVEY - CURRENT GLOBAL PRACTICE FOR SARCOMA SURVEILLANCE FOLLOWING RESECTION OF PRIMARY RETROPERITONEAL, ABDOMINAL, AND PELVIC SARCOMA

(P 346) DETECTION OF GERMLINE VARIANTS IN PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMA USING EXPANDED

(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA

(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?

(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT

(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES

(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM

(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL

(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT

(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS

(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES

(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE

(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.

(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.

(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE

(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE

(P 362) IDENTIFICATION OF A NOVEL INTERACTOR OF ENDOGENOUS SS18-SSX THROUGH MASS SPECTOMETRY-BASED ANALYSIS IN SYNOVIAL SARCOMA CELLS

(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)

(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS

(P 365) MULTIMODAL ANALYSIS OF NUCLEAR AND GENOMIC ORGANIZATION IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS

(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)

(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA

(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS

(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA

(P 370) SYNOVIAL SARCOMA; ROLE OF ADJUVANT CHEMOTHERAPY IN SURGICALLY TREATED PATIETNS WITH NO METASTASIS; A SEER STAT ANALYSIS.

(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY

(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA

(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?

(P 374) ARHGEF4 EXPRESSION IN SOFT TISSUE SARCOMA CORRELATES WITH LOCAL GROWTH PATTERN AND LOCAL RECURRENCE: COMPREHENSIVE GENOMIC ANALYSIS IN SEARCH OF BIOMARKER OF LOCAL GROWTH PATTERN

(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS

(P 376) MULTI-OMIC PROFILING OF LEIOMYOSARCOMA IDENTIFIES MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL

(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS

(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY

(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA

(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES

(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA

(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.

(P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA

(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE

(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA

(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM

(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT

(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.

(P 390) NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ

(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.

(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA

(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS

(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS

(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES

(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY

(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA

(P 399) CRITICAL MOLECULAR PATHWAYS ASSOCIATED WITH DIFFERENT HISTOPATHOLOGY FEATURES AND DETAILED PATTERNS OF IMMUNE CELL INFILTRATES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)

(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4

(P 402) TISSUE PERFUSION AND WOUND HEALING AFTER SOFT TISSUE SARCOMA RESECTION

(P 403) THE IMPACT OF PATIENT, TUMOR, AND TREATMENT FACTORS ON SURVIVAL AND METASTASIS OUTCOMES IN PATIENTS WITH MYXOID LIPOSARCOMA

(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE

(P 406) EXTENSIVE ANALYSIS OF 59 SARCOMA-RELATED FUSION GENES IDENTIFIED PAZOPANIB AS A POTENTIAL INHIBITOR TO COL1A1-PDGFB FUSION GENE

(P 407) PRECISION AND PERSONALIZED TREATMENT FOR SOFT TISSUE SARCOMAS. RESULTS OF A 10 PATIENTS SERIES WITH MOLECULAR PROFILING USING NEXT-GENERATION MASSIVE SEQUENCING

(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES

(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP

(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL

(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.

(P 412) LEIOMYOSARCOMA POLYANEUPLOID CANCER CELLS DEVELOP IN RESPONSE TO CHEMOTHERAPY AND CONTRIBUTE TO CHEMORESISTANCE

(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS

(P 414) GENOMIC ANALYSIS OF EWING SARCOMA AND HERNIA IDENTIFIES A POSITIVE GENETIC CORRELATION AND SUGGESTS BOTH ARE LINKED TO AN HMGA2 VARIANT

(P 415) NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA

(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS

(P 418) GENOMIC AND IMMUNOLOGICAL PROFILING OF PRIMARY AND DISTANT METASTASES OF SOFT TISSUE SARCOMAS

(P 419) AGE ADJUSTED TRENDS IN PATIENTS WITH SYNOVIAL SARCOMA

(P 420) COMPREHENSIVE MOLECULAR PROFILING AND TUMOR MICROENVIRONMENT CHARACTERISTICS OF RADIATION-INDUCED SARCOMA.

(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS

(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS

(P 423) PRIMARY GLIOSARCOMA; IMPACT OF ADJUVANT CHEMO(RADIO)THERAPY ON SURVIVAL OUTCOME

(P 424) INTERNAL TANDEM DUPLICATION OF BCOR (BCOR-ITD) ALTERS THE TUMOR EPIGENOME

(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP

(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES

(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE

(P 428) COMPREHENSIVE GENOMIC PROFILING OF CIC-DUX4 SARCOMA (CDS) CELL LINES AND MODELS

(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR

(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS

(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS

(P 432) LONG-LASTING DISEASE CONTROL WITH TRABECTEDIN IN A CASE OF METASTATIC EWSR1::PATZ1 SARCOMA

(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.

(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS

(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION

(P 436) OUTCOME PROGNOSTICATORS IN ADOLESCENTS AND ADULTS WITH BONE SARCOMAS IN LOW-MIDDLE-INCOME COUNTRIES

(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT

(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL

(P 440) LONG TERM OUTCOMES OF EWING SARCOMA OF THE FOOT AND ANKLE

(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL

(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY

(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS

(P 444) TWO CASES OF BRAIN METASTASES OF CD99 POSITIVE SMALL ROUND BLUE CELL TUMORS

(P 445) ISOTOXIC RADIOTHERAPY DOSE ESCALATION IN UNRESECTABLE PEDIATRIC EWING SARCOMA: A DOSIMETRIC FEASIBILITY STUDY

(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA

(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA

(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING

(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing

(P 450) INVESTIGATING THE THERAPEUTIC POTENTIAL OF SMALL MOLECULE INHIBITOR INOBRODIB AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA

(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL

(P 452) SECONDARY GENOMIC LANDSCAPE OF CIC::DUX4 FUSION SARCOMAS

(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.

(P 454) TREATMENT PATTERNS AND OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH EWING AND UNDIFFERENTIATED ROUND BLUE CELL SARCOMAS IN ALBERTA

(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP

(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS

(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS

(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK

(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

(P 532) MISTOSUS: A PHASE 2 STUDY OF ISCADOR® P IMMUNOTHERAPY FOR PATIENTS WITH RELAPSED OSTEOSARCOMA AND RESECTED PULMONARY METASTASES

(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.

(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA

(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH

(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS

(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA

(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL

(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)

(P 541) ETCTN 10563: PHASE 1 STUDY OF PEPOSERTIB AND LIPOSOMAL DOXORUBICIN FOR ADVANCED OR METASTATIC LEIOMYOSARCOMA AND OTHER SARCOMAS

(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")

(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING

(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)

(P 546) PRELIMINARY CLINICAL RESULTS OF AN ONGOING PHASE II TRIAL: SPRINT (SARCOMA PREOPERATIVE RADIATION WITH SIMULTANEOUS INTEGRATED BOOST)

(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)

(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

(P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN

(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS

(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.

(P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS

(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS

(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS

(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA

(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS

(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)

(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN

(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.

(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.

(P 562) A PHASE 2, SINGLE ARM STUDY OF REGORAFENIB IN METASTATIC/UNRESECTABLE REFRACTORY SYNOVIAL SARCOMAS

(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING

(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS